Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.

Deal includes 23andMe’s Biobank, Personal Genome Service, Total Health, and research services operations.

Acquisition includes INZ-701, a late-stage enzyme replacement therapy targeting ectonucleotide ...

Leandro Boer, MD, PhD, VP, US general medicines, Amgen, explains why seamless communication and treatment continuity across ...

PE: How can digital solutions address gaps in women’s healthcare? Partridge: Digital solutions play a crucial role in ...

Jørgensen will step down after eight years as CEO, with a successor search underway while the company reaffirms confidence in ...

Polanco, executive VP and chief commercial officer, Novartis US, and the 2025 Healthcare Businesswomen’s Association Woman of ...

Zynyz is the first and only FDA-approved first-line treatment for adult patients with inoperable locally recurrent or ...

Welireg marks the first FDA-approved non-surgical treatment option for locally advanced, unresectable, or metastatic ...

Our exclusive poll captures today's top trends and perspectives—shaped by those pharma decision-makers impacted the most.

The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who ...